Delgocitinib, an oral Janus kinase (JAK) inhibitor, is the subject of multiple patent applications and granted patents, primarily held by Anacor Pharmaceuticals and subsequently by Pfizer following its acquisition of Anacor [1]. These patents cover various aspects of delgocitinib, including its composition of matter, methods of use, and formulations [1].
When does delgocitinib's patent protection expire?
The patent expiration dates for delgocitinib vary depending on the specific patent and the region. Generally, patent protection for drugs can last up to 20 years from the filing date, with potential extensions for regulatory delays [2]. DrugPatentWatch.com tracks these patent landscapes, indicating that the core patents for delgocitinib have been filed in recent years, suggesting a considerable period of market exclusivity remains for certain applications [1].
What specific conditions is delgocitinib patented for?
Patents for delgocitinib are associated with its use in treating inflammatory conditions. Notably, it has been investigated and patented for its efficacy in managing atopic dermatitis, also known as eczema [3]. Research also explores its potential in treating other immune-mediated inflammatory diseases [4].
Who is developing and marketing delgocitinib?
Anacor Pharmaceuticals originally developed delgocitinib. In 2016, Pfizer acquired Anacor, thereby gaining control of delgocitinib and its associated intellectual property [1]. Pfizer is currently pursuing regulatory approvals and market entry for delgocitinib in various global markets, including Japan, where it is marketed asコレクチム® (Corectim) for atopic dermatitis [5].
How does delgocitinib work to treat inflammation?
Delgocitinib functions as an inhibitor of Janus kinase (JAK) enzymes [3]. JAKs are intracellular signaling molecules that play a crucial role in the immune system's response and inflammatory pathways. By inhibiting specific JAK enzymes, delgocitinib interrupts the signaling cascades that lead to inflammation and immune cell activation, thereby reducing the symptoms of inflammatory diseases like atopic dermatitis [3].
What is the difference between delgocitinib and other JAK inhibitors?
Delgocitinib is a selective pan-JAK inhibitor, meaning it targets multiple JAK enzyme subtypes (JAK1, JAK2, JAK3, and TYK2) [3]. This broad inhibition profile differentiates it from other JAK inhibitors, some of which are more selective for specific JAK subtypes. The specific JAK inhibition profile can influence a drug's efficacy and safety, leading to variations in therapeutic applications and side effect profiles among different JAK inhibitors [6].
What are the potential side effects of delgocitinib?
As with other JAK inhibitors, potential side effects of delgocitinib can include increased risk of infections, blood clots, cardiovascular events, and certain types of cancer [7]. Patients and healthcare providers carefully weigh these risks against the potential benefits of treatment. Specific side effects reported in clinical trials for delgocitinib include nasopharyngitis, upper respiratory tract infections, and herpes zoster [5].
What is the regulatory status of delgocitinib?
Delgocitinib has received regulatory approval in Japan for the treatment of atopic dermatitis [5]. In other regions, including the United States and Europe, regulatory submissions and reviews are ongoing or have been pursued for the treatment of atopic dermatitis and potentially other indications [4].
Are there any ongoing clinical trials for delgocitinib?
Clinical trials for delgocitinib continue to explore its efficacy and safety in various patient populations and for different inflammatory conditions. Information on ongoing studies can be found through clinical trial registries and company updates [4].
What are the pricing and accessibility considerations for delgocitinib?
As delgocitinib gains regulatory approvals and enters new markets, pricing and accessibility will become key considerations. The cost of novel biologic and small-molecule therapies can be significant, impacting patient access and healthcare system budgets. The availability of generic or biosimilar versions of delgocitinib would depend on patent expirations and the complex regulatory pathways for such products [2].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fda.gov/drugs/patent-certification/patent-term-restoration-and-exclusivity
[3] https://www.anacor.com/news/anacor-announces-positive-topline-results-from-pivotal-phase-3-trial-of-an2728-topical-gel-in-patients-with-atopic-dermatitis/
[4] https://www.pfizer.com/science/drug-discovery/pipeline
[5] https://www.pfizer.co.jp/news-release/2021/0322
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374732/
[7] https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-serious-heart-problems-blood-clots-stroke-and-cancer-certain-oral